The U.S. Food and Drug Administration (FDA) has conditionally approved the Swedish pharmaceutical company’s product Paccal.
Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, a frequently used chemotherapeutics for the treatment of a wide range of cancers in humans. Paccal Vet-CA1 is specifically formulated for use in dogs for the treatment of canine skin and mammary cancers.
“The conditional approval of Paccal Vet-CA1 is a big step forward for veterinary cancer treatment,” commented Julian Aleksov, chief executive officer of Oasmia, in a press release. “In addition, it confirms the potential of our unique patented drug delivery technology XR-17 – a novel derivative of vitamin A that we will be using in clinical trials with our other compounds for a number of human and veterinary indications. This also improves the possibilities to secure the company’s long-term financing.”
Furthermore, Oasmia has signed an agreement with the global health care company Abbott which gives its Animal Health division the exclusive worldwide distribution rights to Paccal Vet-CA1, excluding Russia, Japan and the Commonwealth of Independent States (CIS).
